Sysmex (6869) AI Stock Analysis

• Market Cap: $1.54T
• Dividend Yield: 1.23%
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): 28.6
• Beta (1Y): 0.76
• Revenue Growth: 14.50%
• EPS Growth: 29.02%
• Country: JP
• Employees: 10,042
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 17.72
• Shares Outstanding: 629,473,200
• 10 Day Avg. Volume: 1,237,270
• 30 Day Avg. Volume: 1,093,813
• PEG Ratio: 3.49
• Price to Book (P/B): 3.58
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 31.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $3,349.84
• Price Target Upside: 35.95% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Sysmex's strong financial performance, characterized by robust revenue and profit growth, efficient operations, and a solid balance sheet, is a significant strength. The technical analysis presents mixed signals, with bearish trends but no clear indication of being oversold. The high P/E ratio suggests a premium valuation, which may not be fully justified by its dividend yield. Overall, despite some technical weaknesses and valuation concerns, Sysmex's solid financial foundation supports a relatively strong stock score.

Sysmex Business Overview & Revenue Model

Company Description

Sysmex Corporation (6869) is a leading global company headquartered in Japan that specializes in the development, production, and distribution of diagnostic instruments, reagents, and software. The company primarily operates within the healthcare sector, focusing on laboratory testing and diagnostics. Sysmex's core products include hematology analyzers, urinalysis analyzers, and other clinical diagnostic equipment, which are used in hospitals, laboratories, and research institutions worldwide.

How the Company Makes Money

Sysmex makes money by selling diagnostic instruments, reagents, and software solutions primarily to healthcare providers, including hospitals and clinical laboratories. The company's revenue model is centered around the sale of its innovative diagnostic equipment, which is often complemented by consumable reagents required for the operation of these machines. Additionally, Sysmex generates income through maintenance services and customer support for its products. The company also benefits from strategic partnerships and collaborations with other healthcare and biotechnology firms, which enhance its product offerings and market reach. Its global presence and continuous investment in R&D contribute to its strong market position and sustained revenue growth.

Sysmex Financial Statement Overview

Summary

Sysmex demonstrates a well-rounded financial profile with strong revenue and profit growth, efficient operations, and a solid balance sheet. The company's conservative leverage and robust equity position contribute to its financial stability, while impressive cash flow metrics highlight its ability to generate and manage cash effectively. Overall, Sysmex is well-positioned for sustainable growth and value creation.

Income Statement

Sysmex's income statement exhibits strong revenue growth, with a revenue growth rate of 8.73% in the TTM period over the previous annual period. The gross profit margin is robust at 53.7%, indicating efficient cost management. The net profit margin improved to 11.52% in the TTM period, reflecting increased profitability. Additionally, the EBIT margin of 18.13% and EBITDA margin of 25.29% suggest strong operational efficiency.

Balance Sheet

The balance sheet shows stability with a low debt-to-equity ratio of 0.13, indicating conservative leverage. Return on equity (ROE) is a solid 12.49%, demonstrating effective management of shareholder funds. The equity ratio stands at 70.96%, highlighting a strong capital structure with significant equity backing.

Cash Flow

The cash flow statement reveals a significant improvement in free cash flow, with a growth rate of 282.09% over the previous period. The operating cash flow to net income ratio is 1.45, indicating healthy cash flow generation relative to profits. The free cash flow to net income ratio is also strong at 0.91, underscoring efficient cash conversion.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
501.85B	461.51B	410.50B	363.78B	305.07B	301.98B
	Gross Profit
269.53B	242.50B	216.08B	190.59B	154.30B	159.81B
	EBIT
90.96B	78.38B	73.68B	67.42B	51.79B	55.28B
	EBITDA
126.96B	115.67B	104.95B	96.12B	75.53B	74.28B
	Net Income Common Stockholders
57.79B	49.64B	45.78B	44.09B	31.90B	34.88B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
76.61B	76.61B	70.33B	75.25B	67.57B	57.01B
	Total Assets
618.92B	618.92B	531.07B	483.71B	427.48B	389.29B
	Total Debt
55.34B	55.34B	22.59B	22.28B	21.96B	22.64B
	Net Debt
-20.17B	-20.17B	-46.87B	-51.47B	-44.51B	-33.96B
	Total Liabilities
186.02B	186.02B	142.72B	134.65B	118.81B	110.94B
	Stockholders Equity
432.05B	432.05B	387.67B	348.30B	307.90B	277.68B
Cash Flow		Free Cash Flow
52.41B	13.71B	26.33B	26.70B	33.02B	26.71B
	Operating Cash Flow
83.96B	63.91B	68.83B	58.74B	58.81B	53.18B
	Investing Cash Flow
-47.26B	-54.97B	-51.75B	-35.05B	-31.13B	-25.91B
	Financing Cash Flow
-20.83B	-9.01B	-24.23B	-20.54B	-20.25B	-20.60B

Sysmex Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2464.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6869, the sentiment is Negative. The current price of 2464 is below the 20-day moving average (MA) of 2642.33, below the 50-day MA of 2708.48, and below the 200-day MA of 2799.48, indicating a bearish trend. The MACD of -45.89 indicates Positive momentum. The RSI at 31.90 is Neutral, neither overbought nor oversold. The STOCH value of 14.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6869.

Sysmex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4543	78 Outperform	$4.02T	34.41	8.56%	0.96%	14.23%	26.82%
6869	75 Outperform	$1.54T	28.63	11.84%	1.23%	14.50%	29.02%
4901	74 Outperform	$3.90T	15.16	7.89%	1.96%	7.29%	4.85%
7751	70 Outperform	¥4.35T	25.68		3.44%	9.08%	-33.61%
7733	69 Neutral	¥2.11T	18.18	15.47%	1.04%	7.60%	-66.30%
4523	65 Neutral	$1.05T	22.39	5.34%	4.21%	5.63%	30.61%
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.82%	16.45%	-0.47%